Cargando…

Biological activity of a genetically modified BMP-2 variant with inhibitory activity

BACKGROUND: Alterations of the binding epitopes of bone morphogenetic protein-2 (BMP-2) lead to a modified interaction with the ectodomains of BMP receptors. In the present study the biological effect of a BMP-2 double mutant with antagonistic activity was evaluated in vivo. METHODS: Equine-derived...

Descripción completa

Detalles Bibliográficos
Autores principales: Klammert, Uwe, Nickel, Joachim, Würzler, Kristian, Klingelhöffer, Christoph, Sebald, Walter, Kübler, Alexander C, Reuther, Tobias
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646720/
https://www.ncbi.nlm.nih.gov/pubmed/19187528
http://dx.doi.org/10.1186/1746-160X-5-6
_version_ 1782164883997982720
author Klammert, Uwe
Nickel, Joachim
Würzler, Kristian
Klingelhöffer, Christoph
Sebald, Walter
Kübler, Alexander C
Reuther, Tobias
author_facet Klammert, Uwe
Nickel, Joachim
Würzler, Kristian
Klingelhöffer, Christoph
Sebald, Walter
Kübler, Alexander C
Reuther, Tobias
author_sort Klammert, Uwe
collection PubMed
description BACKGROUND: Alterations of the binding epitopes of bone morphogenetic protein-2 (BMP-2) lead to a modified interaction with the ectodomains of BMP receptors. In the present study the biological effect of a BMP-2 double mutant with antagonistic activity was evaluated in vivo. METHODS: Equine-derived collagenous carriers were loaded with recombinant human BMP-2 (rhBMP-2) in a well-known dose to provide an osteoinductive stimulus. The study was performed in a split animal design: carriers only coupled with rhBMP-2 (control) were implanted into prepared cavities of lower limb muscle of rats, specimens coupled with rhBMP-2 as well as BMP-2 double mutant were placed into the opposite limb in the same way. After 28 days the carriers were explanted, measured radiographically and characterized histologically. RESULTS: As expected, the BMP-2 loaded implants showed a typical heterotopic bone formation. The specimens coupled with both proteins showed a significant decreased bone formation in a dose dependent manner. CONCLUSION: The antagonistic effect of a specific BMP-2 double mutant could be demonstrated in vivo. The dose dependent influence on heterotopic bone formation by preventing rhBMP-2 induced osteoinduction suggests a competitive receptor antagonism.
format Text
id pubmed-2646720
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26467202009-02-24 Biological activity of a genetically modified BMP-2 variant with inhibitory activity Klammert, Uwe Nickel, Joachim Würzler, Kristian Klingelhöffer, Christoph Sebald, Walter Kübler, Alexander C Reuther, Tobias Head Face Med Research BACKGROUND: Alterations of the binding epitopes of bone morphogenetic protein-2 (BMP-2) lead to a modified interaction with the ectodomains of BMP receptors. In the present study the biological effect of a BMP-2 double mutant with antagonistic activity was evaluated in vivo. METHODS: Equine-derived collagenous carriers were loaded with recombinant human BMP-2 (rhBMP-2) in a well-known dose to provide an osteoinductive stimulus. The study was performed in a split animal design: carriers only coupled with rhBMP-2 (control) were implanted into prepared cavities of lower limb muscle of rats, specimens coupled with rhBMP-2 as well as BMP-2 double mutant were placed into the opposite limb in the same way. After 28 days the carriers were explanted, measured radiographically and characterized histologically. RESULTS: As expected, the BMP-2 loaded implants showed a typical heterotopic bone formation. The specimens coupled with both proteins showed a significant decreased bone formation in a dose dependent manner. CONCLUSION: The antagonistic effect of a specific BMP-2 double mutant could be demonstrated in vivo. The dose dependent influence on heterotopic bone formation by preventing rhBMP-2 induced osteoinduction suggests a competitive receptor antagonism. BioMed Central 2009-02-02 /pmc/articles/PMC2646720/ /pubmed/19187528 http://dx.doi.org/10.1186/1746-160X-5-6 Text en Copyright © 2009 Klammert et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Klammert, Uwe
Nickel, Joachim
Würzler, Kristian
Klingelhöffer, Christoph
Sebald, Walter
Kübler, Alexander C
Reuther, Tobias
Biological activity of a genetically modified BMP-2 variant with inhibitory activity
title Biological activity of a genetically modified BMP-2 variant with inhibitory activity
title_full Biological activity of a genetically modified BMP-2 variant with inhibitory activity
title_fullStr Biological activity of a genetically modified BMP-2 variant with inhibitory activity
title_full_unstemmed Biological activity of a genetically modified BMP-2 variant with inhibitory activity
title_short Biological activity of a genetically modified BMP-2 variant with inhibitory activity
title_sort biological activity of a genetically modified bmp-2 variant with inhibitory activity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646720/
https://www.ncbi.nlm.nih.gov/pubmed/19187528
http://dx.doi.org/10.1186/1746-160X-5-6
work_keys_str_mv AT klammertuwe biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity
AT nickeljoachim biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity
AT wurzlerkristian biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity
AT klingelhofferchristoph biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity
AT sebaldwalter biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity
AT kubleralexanderc biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity
AT reuthertobias biologicalactivityofageneticallymodifiedbmp2variantwithinhibitoryactivity